Recently At InnoSer
OUR INNOVATIVE METHODS
Combining In-Vivo And In-Vitro
By our state-of-the-art methods from organoids to genetically engineered mice, we provide reliability and transferability in your results.
Low success rates of drugs that are able to go from bench to the clinic continue to disappoint not only researchers and pharmaceutical companies but also patients and their families. The resulting expenses affect the costs of all drugs that reach the market.
This calls for more stringent criteria at the preclinical phase, ensuring only the drugs that are effective and safe for humans continue to the clinical phases. InnoSer excels in combining in vitro and in vivo disease modelling to offer the most reliable screening platforms.
By developing in-vitro technologies and knowledge that offer higher predictive capacity, we support the transition to a world that relies less on animal testing.
GET IN TOUCH WITH US
Tell Us About Your Work
We always keep close contact with our customers to identify and understand their needs better. All our services can be customized for your project requirements.
OUR CLIENTS ABOUT US
Academic And Commercial Expertise
“We truly enjoyed working with the InnoSer team. They bring an outstanding scientific knowledge into the oncology field in combination with high flexibility. InnoSer provided us with and executed a preclinical study project tailored to our needs, and within the agreed timelines. We will definitely work with InnoSer for our future drug development needs.”
Ad van de Gorp PhD, CEO Cythura Therapeutics
“Starting a biotech company was something completely new for me. InnoSer supported me in developing the study protocol and with all additional hassle like ethical protocols, logistics, ordering study materials etc. We worked closely with the InnoSer staff and I truly appreciate their professionalism and dedication.”
Joost van Bree, CEO Saillant Therapeutics